Eric Barros

Featured in: Favicon

Articles

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial - Nature Medicine

May 13, 2024 | nature.com | Ildiko Lingvay |Eric Barros |Helen M. Colhoun |Cintia Cercato |A. Michael Lincoff |Jorge Plutzky

AbstractIn the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial - Nature Medicine

Aug 27, 2023 | nature.com | Barry A. Borlaug |Eric Barros |Sanjiv Shah |Subodh Verma |Walter P. Abhayaratna |Justin A. Ezekowitz | +5 more

AbstractIn the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.